Health
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of TN-401 Activity in Heart Muscle Cells PRIME Designation Granted by European Medicines Agency Tenaya Management to Host a Webcast Conference Call to Review Results on Friday, May 15 at 10:30 a.m. ET / 7:30 a.m. PT Following Late-Breaker Presentation at ASGCT 2026 SOUTH SAN FRANCISCO
About this update from Tenaya Therapeutics, Inc.
[{"type":"image","alt":"Tenaya Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenaya Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aaM78VHLlwFUIjp7XWFupw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6","width":300,"height":108},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/aaM78VHLlwFUIjp7XWFupw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6","width":300,"height":108}},"lazy":false},{"type":"text","content":"All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count ","length":104,"tagName":"p"},{"type":"text","content":"TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses","length":73,"tagName":"p"},{"type":"text","content":"Post-dose Biopsies Provide Evidence of TN-401 Activity in Heart Muscle Cells ","length":76,"tagName":"p"},{"type":"text","content":"PRIME Designation Granted by European Medicines Agency","length":54,"tagName":"p"},{"type":"text","content":"Tenaya Management to Host a Webcast Conference Call to Review Results on Friday, May 15 at 10:30 a.m. ET / 7:30 a.m. PT Following Late-Breaker Presentation at ASGCT 2026","length":171,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, presented interim data from the ongoing RIDGE™-1 Phase 1b/2 clinical trial of TN-401 gene therapy at the American Society of Gene and Cell Therapies (ASGCT) 2026 Annual Meeting. In adults with arrhythmogenic right ventricular cardiomyopathy (ARVC), caused by mutations in the plakophilin-2 (PKP2) gene, treatment with a single infusion of TN-401 at either the 3E13 vg/kg (Cohort 1) or 6E13 vg/kg (Cohort 2) dose resulted in consistent and deep reductions in premature ventricular contractions (PVCs) in all six Cohort 1 and 2 patients. TN-401 was well tolerated at both d...